ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company based in South San Francisco that develops therapies for cancer treatment. Its product candidates include ORIC-533, ORIC-944, and ORIC-114, which target cancer resistance mechanisms. The company also has license and collaboration agreements with Voronoi Inc. and Mirati Therapeutics, Inc.